You have 9 free searches left this month | for more free features.

Ph ALL relapsed

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Acute Lymphoblastic Leukemia Trial (chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 19, 2023

Acute Lymphoblastic Leukemia Trial in Suzhou (cladribine, cytarabine,venetoclax)

Recruiting
  • Acute Lymphoblastic Leukemia
  • cladribine, cytarabine,venetoclax
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 22, 2022

Acute Lymphoblastic Leukemia (ALL) Trial (Nilotinib)

No longer available
  • Acute Lymphoblastic Leukemia (ALL)
  • (no location specified)
Aug 5, 2022

Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia Trial in

Not yet recruiting
  • Lymphoblastic Leukemia, Acute, Childhood
  • +3 more
  • Olverembatinib, APG-2575, Dexamethasone
  • Hefei, Anhui, China
  • +3 more
Aug 8, 2022

Lymphoma Leukemia Trial in Minneapolis (allogeneic CAR19 regulatory T cells (CAR19-tTreg))

Not yet recruiting
  • Lymphoma Leukemia
  • allogeneic CAR19 regulatory T cells (CAR19-tTreg)
  • +2 more
  • Minneapolis, Minnesota
    Masonic Cancer Center - University of Minnesota
Dec 6, 2022

B-cell Acute Lymphoblastic Leukemia Trial in Tampa, Durham, Winston-Salem (Blinatumomab)

Withdrawn
  • B-cell Acute Lymphoblastic Leukemia
  • Tampa, Florida
  • +2 more
Feb 14, 2022

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute

Recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 16, 2022

B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Azacitidine Injection
  • +2 more
  • (no location specified)
Oct 15, 2023

Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease Trial in Tianjin (the usage of Olverembatinib combined with Inotuzumab

Not yet recruiting
  • Ph+ ALL
  • +2 more
  • the usage of Olverembatinib combined with Inotuzumab Ozogamicin
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital, Chinese Acade
Oct 30, 2022

Ph+ ALL Trial in China (Olverembatinib, Imatinib)

Recruiting
  • Ph+ ALL
  • Chongqing, Chongqing, China
  • +8 more
Sep 22, 2023

T-lymphoblastic Lymphoma, T-ALL Trial in Shanghai (CAR-T)

Recruiting
  • T-lymphoblastic Lymphoma
  • T-ALL
  • CAR-T
  • Shanghai, China
    Shanghai Ruijin Hospital
Nov 14, 2023

Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) Trial in Tokyo (Nilotinib)

Completed
  • Chronic Myelogenous Leukemia
  • Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
  • Tokyo, Japan
    Novartis Investigative Site
Dec 6, 2020

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +7 more
  • Blinatumomab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Worldwide (Nilotinib)

Completed
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Bordeaux, Aquitaine, France
  • +11 more
Dec 6, 2020

Philadelphia-Positive ALL Trial in Suzhou (Olverembatinib)

Not yet recruiting
  • Philadelphia-Positive ALL
  • Suzhou, Jiangsu, China
    First Affiliated Hospital of Soochow University
Jul 1, 2023

CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL Trial in Suzhou (Treatment)

Recruiting
  • CAR
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 27, 2022

Acute Lymphoblastic Leukemia, Adult Trial in Caba (Evaluation of survival and toxicities in AYA Ph-negative ALL patients

Recruiting
  • Acute Lymphoblastic Leukemia, Adult
  • Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.
  • Paraná, Entre Ríos, Argentina
  • +1 more
Dec 29, 2022

B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • HY004
  • +2 more
  • (no location specified)
Aug 18, 2023

B Acute Lymphoblastic Leukemia Trial in Suzhou (Blinatumomab)

Recruiting
  • B Acute Lymphoblastic Leukemia
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Nov 1, 2022

Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL, Newly Diagnosed Trial in Czechia (Blinatumomab)

Active, not recruiting
  • Lymphoblastic Leukemia, Acute, Adult
  • +2 more
  • Brno, Czechia
  • +4 more
Aug 3, 2022

B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)

Not yet recruiting
  • B Precursor Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
  • (no location specified)
Sep 25, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • QH103 Cell Injection
  • +2 more
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Sep 21, 2023

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Tianjin (Olverembatinib, Venetoclax, prednisone)

Recruiting
  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Oct 21, 2022

Relapsed Adult ALL, Relapsed Adult AML Trial in Changchun (Plerixafor)

Active, not recruiting
  • Relapsed Adult ALL
  • Relapsed Adult AML
  • Changchun, Jilin, China
    First Hospital of Jilin University
Nov 19, 2023

Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL),

Recruiting
  • Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)
  • +2 more
  • Phoenix, Arizona
  • +69 more
Aug 23, 2022